Record funding for Finnish bioimaging

Euro-BioImaging Finland, the research infrastructure of Finnish bioimaging, has received funding of about EUR 28 million from the Research Council of Finland.
Euro-BioImaging Finland consists of the best imaging units from seven universities and three university hospitals. The services of the research infrastructure cover 56 technologies ranging from laser microscopy of individual molecules to PET imaging of an entire human.
With the funding, Euro-BioImaging Finland will develop new imaging technologies and services, and new methods based on artificial intelligence (AI), it states.
Coordinated by Turku BioImaging
The infrastructure is coordinated by Turku BioImaging, a joint unit of Åbo Akademi University and University of Turku, and it belongs to the pan-European Euro-BioImaging organization. In addition to Euro-BioImaging Finland, Finland hosts the entire international Euro-BioImaging infrastructure, with the headquarters in Turku leading the international organization operating in 19 countries.
Lighthouses
The funding is related to the infrastructure being selected to the national roadmap of research infrastructures 2025-2028. In addition, Euro-BioImaging Finland was chosen as one of six Finland’s highest quality infrastructures, so called lighthouses – forerunners with broad societal impact.
Openly accessible to everyone
All services of Euro-BioImaging Finland are openly accessible to everyone. Annually, the infrastructure is used by thousands of scientists around Finland and the world, and dozens of companies ranging from small startups to international pharma giants.
This will support both cutting-edge fundamental research and translational applications.
“This will support both cutting-edge fundamental research and translational applications. As part of this effort, our unit contributes to several EU-funded and other international multidisciplinary collaborative research projects and collaborates closely with HUS clinicians to apply imaging technologies in studying the biology and drug responses of patient cells,” says Vilja Pietiäinen, the head of the FIMM High Content Imaging and Analysis core unit.
Published: April 23, 2025